Literature DB >> 21052078

Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future.

Anthony E Lang1.   

Abstract

Neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease represent a crucial and exponentially increasing challenge to health care systems throughout the world. There is an urgent need for effective treatments that will both delay their onset and slow their inexorable progression. Many obstacles stand in the way of realizing these goals. It is expected that future advances will have a major impact on how and when the diagnosis will be made. It is hoped that these will eventually make it possible to initiate effective disease-modifying therapies long before the neurodegenerative process becomes established and symptomatic.

Entities:  

Mesh:

Year:  2010        PMID: 21052078     DOI: 10.1038/nm.2220

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  51 in total

Review 1.  Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans.

Authors:  Paul S Aisen; Ronald C Petersen; Michael C Donohue; Anthony Gamst; Rema Raman; Ronald G Thomas; Sarah Walter; John Q Trojanowski; Leslie M Shaw; Laurel A Beckett; Clifford R Jack; William Jagust; Arthur W Toga; Andrew J Saykin; John C Morris; Robert C Green; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

Review 2.  Looking backward to move forward: early detection of neurodegenerative disorders.

Authors:  Steven T DeKosky; Kenneth Marek
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

3.  Olfactory loss may be a first sign of idiopathic Parkinson's disease.

Authors:  Antje Haehner; Thomas Hummel; Cornelia Hummel; Ulrike Sommer; Susann Junghanns; Heinz Reichmann
Journal:  Mov Disord       Date:  2007-04-30       Impact factor: 10.338

4.  A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.

Authors:  C Warren Olanow; Robert A Hauser; Joseph Jankovic; William Langston; Anthony Lang; Werner Poewe; Eduardo Tolosa; Fabrizio Stocchi; Eldad Melamed; Eli Eyal; Olivier Rascol
Journal:  Mov Disord       Date:  2008-11-15       Impact factor: 10.338

Review 5.  Genetic animal models of Parkinson's disease.

Authors:  Ted M Dawson; Han Seok Ko; Valina L Dawson
Journal:  Neuron       Date:  2010-06-10       Impact factor: 17.173

Review 6.  Probing the biology of Alzheimer's disease in mice.

Authors:  Karen H Ashe; Kathleen R Zahs
Journal:  Neuron       Date:  2010-06-10       Impact factor: 17.173

Review 7.  Animal models of amyloid-beta-related pathologies in Alzheimer's disease.

Authors:  Ola Philipson; Anna Lord; Astrid Gumucio; Paul O'Callaghan; Lars Lannfelt; Lars N G Nilsson
Journal:  FEBS J       Date:  2010-02-03       Impact factor: 5.542

8.  Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.

Authors:  Alan L Whone; Ray L Watts; A Jon Stoessl; Margaret Davis; Sven Reske; Claude Nahmias; Anthony E Lang; Olivier Rascol; Maria J Ribeiro; Philippe Remy; Werner H Poewe; Robert A Hauser; David J Brooks
Journal:  Ann Neurol       Date:  2003-07       Impact factor: 10.422

Review 9.  Chipping away at diagnostics for neurodegenerative diseases.

Authors:  Clemens R Scherzer
Journal:  Neurobiol Dis       Date:  2009-03-10       Impact factor: 5.996

10.  Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis.

Authors:  Berend Arnold Ploeger; Nicholas H G Holford
Journal:  Pharm Stat       Date:  2009 Jul-Sep       Impact factor: 1.894

View more
  21 in total

Review 1.  Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed?

Authors:  Sagar Kansara; Akash Trivedi; Sheng Chen; Joseph Jankovic; Weidong Le
Journal:  J Neural Transm (Vienna)       Date:  2012-06-26       Impact factor: 3.575

2.  Learning from genetic forms of neurodegeneration.

Authors:  Alexis Brice
Journal:  Nat Med       Date:  2010-12       Impact factor: 53.440

3.  Neurodegeneration and the neurovascular unit.

Authors:  Berislav V Zlokovic
Journal:  Nat Med       Date:  2010-12       Impact factor: 53.440

4.  Neurodegeneration and the neuroimmune system.

Authors:  Joseph El Khoury
Journal:  Nat Med       Date:  2010-12       Impact factor: 53.440

Review 5.  Neurotrophic natural products: chemistry and biology.

Authors:  Jing Xu; Michelle H Lacoske; Emmanuel A Theodorakis
Journal:  Angew Chem Int Ed Engl       Date:  2013-12-18       Impact factor: 15.336

Review 6.  Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.

Authors:  Amaal AlDakheel; Lorraine V Kalia; Anthony E Lang
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

7.  Induction of heat shock proteins in differentiated human neuronal cells following co-application of celastrol and arimoclomol.

Authors:  Catherine A S Deane; Ian R Brown
Journal:  Cell Stress Chaperones       Date:  2016-06-08       Impact factor: 3.667

Review 8.  Non-human primate models of PD to test novel therapies.

Authors:  Marc Morissette; Thérèse Di Paolo
Journal:  J Neural Transm (Vienna)       Date:  2017-04-08       Impact factor: 3.575

9.  Nanotherapeutics Engineered to Cross the Blood-Brain Barrier for Advanced Drug Delivery to the Central Nervous System.

Authors:  Jinhwan Kim; Song Ih Ahn; YongTae Kim
Journal:  J Ind Eng Chem       Date:  2019-01-28       Impact factor: 6.064

Review 10.  Elucidating Critical Proteinopathic Mechanisms and Potential Drug Targets in Neurodegeneration.

Authors:  Khalid Bashir Dar; Aashiq Hussain Bhat; Shajrul Amin; Bilal Ahmad Reshi; Mohammad Afzal Zargar; Akbar Masood; Showkat Ahmad Ganie
Journal:  Cell Mol Neurobiol       Date:  2019-10-04       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.